Skip to Content
Merck
All Photos(1)

Key Documents

20050-U

Supelco

ORBO™ 608 Amberlite™ XAD®-2 (20/50) 150/75 mg

W,W,W separators, O.D. × L 8 mm × 110 mm, pkg of 50 ea

Synonym(s):

ORBO™ Amberlite™ XAD-2 Tube

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
12190000
NACRES:
NB.24

material

W,W,W separators

Agency

NIOSH 2514,2543,5514

product line

Amberlite™
ORBO™

composition

Bed A, 150 mg
Bed B, 75 mg

packaging

pkg of 50 ea

manufacturer/tradename

ORBO™ 608

technique(s)

active air sampling: suitable

O.D. × L

8 mm × 110 mm

matrix

XAD-2

particle size

20-50 mesh

application(s)

air monitoring
environmental
industrial hygiene

Looking for similar products? Visit Product Comparison Guide

General description

ORBO sorbent tubes (W,W,W separators, O.D. × L 8 mm × 110 mm) contain two beds of the same selective adsorbent separated by glass wool or foam, for gas and vapor sampling. The dual-layer or two-bed construction of the tube allows for any sample breakthrough to be captured in the smaller back-up bed.

Legal Information

Amberlite is a trademark of DuPont de Nemours, Inc.
ORBO is a trademark of Sigma-Aldrich Co. LLC
XAD is a registered trademark of The Dow Chemical Company or an affiliated company of Dow

Storage Class Code

13 - Non Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

K Flo et al.
Scandinavian journal of clinical and laboratory investigation, 55(8), 715-721 (1995-12-01)
Elevated extracellular cGMP levels have been observed in various clinical conditions, and the analyte has been proposed as a diagnostic marker of cardiovascular as well as malignant diseases. However, the use of extracellular cGMP as a pathophysiological marker requires detailed
Bjørn T Moe et al.
Anticancer research, 29(4), 1047-1052 (2009-05-06)
Endometrial hyperplasia is a precursor lesion of endometrial carcinoma. Clinical studies of endometrial hyperplasia have shown that levonorgestrel (LNG) is more therapeutically effective than medroxyprogesterone acetate (MPA). The present pharmacological in vitro study was performed to compare progestin effects on
A Orbo et al.
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 117(7), 972-976 (1997-03-10)
The development of female steroid hormone-related neoplasms such as gynaecologic and mammary cancers is influenced by hormones administered exogenously. Hormonal contraceptives and hormone replacement therapy both affect the risk of developing cancers in the endometrium, cervix, ovarium, and mammary glands.
[Explorative abrasion--obsolete?].
A Orbo
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 111(19), 2397-2398 (1991-08-20)
Anne Ørbo et al.
British journal of cancer, 115(6), 725-730 (2016-08-19)
The aim of the present study was to investigate whether changes in the tissue expression of human epididymis-specific protein 4 (HE4) could predict therapy resistance and relapse after progestin hormone therapy for medium- and low-risk endometrial hyperplasia. Endometrial biopsies were
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service